Oncology Ventures CEO Peter Buhl Jensen buys shares in the Company

World News: . []

The current OV product portfolio includes LiPlaCis a liposomal formulation of cisplatin in an ongoing Phase 2 trial for breast and prostate cancer 2X-121 a PARP inhibitor in an ongoing Phase 2 for breast cancer; dovitinib a post phase 3 product which w...

More news and information about Oncology Venture A/S

Published By:

Globe Newswire: 08:36 GMT Thursday 6th December 2018

Published: .

Search for other references to "oncology" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us